<DOC>
	<DOC>NCT02809989</DOC>
	<brief_summary>The aim of this non-interventional study is to extend the knowledge on effectiveness of Ovaleap® (number of oocytes and pregnancy rate) during routine IVF- or ICSI-treatment using a Gonadotropin-releasing hormone (GnRH) antagonist protocol in a large number of patients.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.</brief_title>
	<detailed_description />
	<criteria>Women with a medical indication for an ovarian stimulation therapy for the purposes of an IVF or ICSI. Firsttime ovarian stimulating therapy for an IVF or ICSI. Ovarian stimulation therapy exclusively with Ovaleap®. GnRH antagonist protocol. BodyMassIndex (BMI) &lt; 30 kg/m2. Duration of menstrual cycle 24 35 days. Additional criteria apply, please contact the investigator for more information Combined application of IVF and ICSI Ovarian hyperstimulation with Ovaleap® with a consecutive "social freezing". Polycystic ovary syndrome (PCOS). Endometriosis (AFS (American Fertility Society) grade 3 and 4). Uterine myoma (intramural &gt; 4 cm, submucosal). Hydrosalpinx (on one side or both sides).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>